Locking solutions for hemodialysis catheters; heparin and citrate--a position paper by ASDIN.
Research article published in Seminars in dialysis (2008)
Abstract
There is wide variation in the use of solutions to "lock" or fill tunneled central venous catheters for dialysis. Some centers use undiluted heparin concentrations ranging from 1000 to 10,000 U/ml and other centers place from 1000 to 10,000 U per lumen. Based on available evidence, it appears that heparin 1000 U/ml, or 4% sodium citrate are suitable choices for lock solution to maintain patency of tunneled central venous catheters for dialysis. Risks from systemic anticoagulation are lower with heparin 1000 U/ml and 4% sodium citrate, compared with higher concentrations of heparin (5000 and 10,000 U/ml). The need for use of tissue plasminogen activator for maintaining catheter patency is increased by using heparin lock at 1000 U/ml, vs. higher concentrations. Higher concentrations of heparin lock should be reserved for patients who have evidence of catheter occlusion or thrombosis when heparin is used at 1000 U/ml. Similar choices for lock solution are sensible for acute hemodialysis catheters. When heparin is used for catheter lock, the injected volume should not exceed the internal volume of the catheter.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
There is wide variation in the use of solutions to "lock" or fill tunneled central venous catheters for dialysis. Some centers use undiluted heparin concentrations ranging from 1000 to 10,000 U/ml and other centers place from 1000 to 10,000 U per lumen.
Why This Matters for Hirudotherapy
This article evaluates locking solutions — heparin (1000–10,000 U/mL) and 4% sodium citrate — for maintaining patency of tunneled central venous hemodialysis catheters, recommending lower-concentration heparin or citrate to minimize systemic anticoagulation risks compared with higher heparin concentrations. The abstract also notes that the need for tissue plasminogen activator increases when using heparin at 1000 U/mL versus higher concentrations. For ASH, there is no direct relevance: the abstract makes no mention of leeches, hirudin, hirudotherapy, or any leech-derived compounds. CAVEAT: No defensible leech or hirudin connection exists in this abstract; the topic concerns dialysis catheter management using conventional anticoagulants unrelated to leech biology.
Citation
Locking solutions for hemodialysis catheters; heparin and citrate--a position paper by ASDIN.
Moran et al. · Seminars in dialysis, 2008
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026